{"organizations": [], "uuid": "5d47fe6dc70e6946ebce8187caad9c0e8fcb7212", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-acelrx-pharmaceuticals-reports-q1/brief-acelrx-pharmaceuticals-reports-q1-loss-per-share-0-23-idUSASC0A13S", "country": "US", "domain_rank": 408, "title": "BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.072, "site_type": "news", "published": "2018-05-10T04:47:00.000+03:00", "replies_count": 0, "uuid": "5d47fe6dc70e6946ebce8187caad9c0e8fcb7212"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-acelrx-pharmaceuticals-reports-q1/brief-acelrx-pharmaceuticals-reports-q1-loss-per-share-0-23-idUSASC0A13S", "ord_in_thread": 0, "title": "BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acelrx pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nancial", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - AcelRx Pharmaceuticals Inc:\n* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.23 * Q1 EARNINGS PER SHARE VIEW $-0.24 â€” THOMSON REUTERS I/B/E/S\n* EXPECTED ACCEPTANCE OF DSUVIA NDA BY FDA IN Q2 2018 * POTENTIAL EUROPEAN COMMISSION APPROVAL OF DZUVEO IN Q3 2018\n* MARCH 31, 2018 CASH AND SHORT-TERM INVESTMENTS BALANCE OF $51.2 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T04:47:00.000+03:00", "crawled": "2018-05-10T17:36:13.000+03:00", "highlightTitle": ""}